Clinical trials: insulin glargine
Diabetes, Diabetes Mellitus, Type 2
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin…
- Trial name
- INITIATE (NCT00598793)
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 27 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
The rationale of the study is to determine: the first dose and the titration of basal insulin the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.
- Trial name
- NCT00349986
- Testing
- Insuline glargine
- Where
- Hungary
- Volunteers
- 4 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three…
- Trial name
- NCT00960661
- Testing
- exenatide, insulin lispro, Metformin
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 1,036 people
- Sponsor
- AstraZeneca
Healthy
A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar…
- Trial name
- NCT03555305
- Testing
- Insulin Glargine, Lantus
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hyperglycemia
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
- Trial name
- HMH (NCT01136746)
- Testing
- Human regular insulin, Insulin lispro, Insulin glargine
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Type1 Diabetes
Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate equivalence in exposure to insulin glargine given as test formulation T and reference formulation R in steady state conditions after 6 once-daily subcutaneous (SC) doses Secondary Objective: To…
- Trial name
- NCT01838083
- Testing
- Insulin glargine new formulation HOE901
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
- Trial name
- NCT00976391
- Testing
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Where
- 209 sites in United States, Brazil and 12 more
- Volunteers
- 586 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes
Patients with diabetes treated with insulin often gain weight, which may deter patients from adhering to insulin treatment. Detemir is one type of long acting insulin approved by the Food and Drug Administration for use in people…
- Trial name
- NCT00659165
- Testing
- Insulin Detemir, Insulin Glargine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes
Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes
This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and their effect on blood glucose control, versus…
- Trial name
- NCT00971659
- Testing
- insulin glargine + exenatide + preexisting metformin, insulin glargine + sitagliptin + preexisting metformin, insulin glargine + preexisting metformin
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 2
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes.
- Trial name
- SUSTAIN 11 (NCT03689374)
- Testing
- Semaglutide, Insulin aspart, Insulin glargine U100
- Where
- 210 sites in Bosnia and Herzegovina, Bulgaria and 19 more
- Volunteers
- 2,274 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications…
- Trial name
- NCT03338010
- Testing
- LY2963016, Lantus®
- Where
- 32 sites in China
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetic Patients
Primary: To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c < 7%) Secondary: To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic…
- Trial name
- TARGET (NCT00347100)
- Testing
- Insulin Glargine, Glyburide, Glyclazide
- Where
- China
- Volunteers
- 387 people
- Sponsor
- Sanofi
Diabetes Mellitus, Insulin-Dependent
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
- Trial name
- NCT00115570
- Testing
- Insulin glulisine, insulin lispro, insulin glargine
- Where
- United States
- Volunteers
- 572 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess the postprandial glucodynamic response to 2 doses of insulin glargine/lixisenatide fixed-ratio combination compared to placebo in Japanese patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02713477
- Testing
- Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010, Insulin glargine HOE901
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the safety and tolerability of two dose levels of a new insulin glargine formulation in a once-daily multiple dosing regimen Secondary Objective: To compare the pharmacokinetic and pharmacodynamic…
- Trial name
- NCT01349855
- Testing
- Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus (T2DM)
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Primary objective: Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: Treatment satisfaction
- Trial name
- ELDERLY-T (NCT05607160)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Sanofi
Evidence of Liver Transplantation, Hyperglycemia
Study of Glycemic Control on Liver Transplantation Outcomes
Many but not all studies have shown improvement in morbidity and mortality with intensive glycemic management postoperatively. In this study, the investigators propose to determine whether improved glycemic control using…
- Conditions
- Evidence of Liver Transplantation, Hyperglycemia, Rejection
- Trial name
- NCT01211730
- Testing
- Insulin
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Northwestern University
COPD, Hyperglycemia
Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards
Patients with chronic obstructive pulmonary disease (COPD) are commonly admitted to hospital with exacerbations of their lung disease.
- Trial name
- IPS2008 (NCT00764556)
- Testing
- Insulin
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St George's, University of London
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
- Trial name
- PRONTO-Peds (NCT03740919)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 111 sites in United States, Austria and 16 more
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company